Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 12/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723622 | 0.78 | F2RL3 (0.43) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL1671967 | 0.73 | TSHR (0.34) | SMN1; SMN2MAPTALOX15ALDH1A1LMNA | |
| SCHEMBL1672605 | 0.69 | TP53 (0.40) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL28415812 | 0.66 | F2RL3 (0.44) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL8813676 | 0.64 | NPC1 (0.57) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL25087591 | 0.63 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1LMNATSHR | |
| SCHEMBL12690055 | 0.62 | TP53 (0.40) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL12689937 | 0.62 | TP53 (0.35) | TP53SMN1; SMN2MAPTF2RL3NPC1 | |
| SCHEMBL16397831 | 0.60 | TACR1 (0.36) | ALDH1A1NFKB1 | |
| SCHEMBL1672397 | 0.59 | POLB (0.53) | SMN1; SMN2MAPTNPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491045-B1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | EP | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2491045-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Pharma S.A. (BE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047860-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | CYP3A4, CYP3A43, CYP3A7 | TP53 2687/4885SMN1; SMN2 2662/4885MAPT 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.